DESCRIPTION

Used for the quantitative determination of Secukinumab concentration in serum and plasma.

PRINCIPLE OF THE ASSAY

This assay employs the quantitative indirect enzyme immunoassay technique. Recombinant Human IL17A has been pre-coated onto a microplate. Standards or samples are pipetted into the wells and any Secukinumab present is bound by the immobilized protein. After washing away any unbound substances, a biotin-labeled Mouse Anti-Human IgG antibody is added to the wells. After washing away any unbound substances, Streptavidin-HRP is added to the wells. Following a wash to remove any unbound enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of Secukinumab bound in the initial step. The color development is stopped and the intensity of the color is measured.

PRECISION

Intra-Assay Precision (Precision within an assay): <10% Three samples of known concentration were tested sixteen times on one plate to assess intra-assay precision. Inter-Assay Precision (Precision between assays): <15% Three samples of known concentration were tested in twenty four separate assays to assess inter-assay precision.

Sample		1	2	3	1	2	3
n		16	16	16	24	24	24
Mean (ng/mL)		7621.5	1720.7	952.0	6774.0	1688.3	1001.7
Standard deviation		264.2	60.8	42.0	372.9	134.7	65.9
CV \(%\)		3.5	3.5	4.4	5.5	8.0	6.6

RECOVERY

The recovery of Secukinumab spiked to three different levels in human serum samples throughout the range of the assay was evaluated.

Sample	Dilution factor	Average (%)	Range (%)
Human serum (n=3)	1:10	97	84-110
	1:20	93	81-104

LINEARITY

To assess the linearity of the assay, human serum samples were spiked with high concentrations of Secukinumab and diluted with the Standard Diluent to produce samples with values within the dynamic range of the assay.

Sample	Dilution factor	Average (%)	Range (%)
Human serum (n=3)	1:2	100	97-104
	1:4	108	102-118
	1:8	109	101-119